Antiviral remodevir should not be used as routine treatment for patients with Covid-19, one of the world’s leading organizations representing intensive care physicians, developed by the US company Gilead, one of the intensive care units. Has a hard blow to the drugs.
Remedisavir, also known as vecleri, and the steroid dexametasone are the only drugs licensed to treat patients with COVID-19 worldwide. But the largest study on the effectiveness of Remedisvir, conducted by the World Health Organization (WHO), was presented on October 15. Unlike previous tests, it had little to no effect.
“Remedisvir is now classified as a drug that you should not use regularly in patients with COVID-19,” said the European Society of Critical Care Medicine (ESICM) in light of new provisional data from the trial of solidarity from WHO President Jozef Kseyoglu said. In an interview with Reuters.
Kaseikoglu said the recommendation would be discussed in a scientific article on COVID therapy that ESICM is preparing with another intensive care organization, the Society of Critical Care Medicine, which is expected to be published by January.
An earlier version of the document released in March said there was not enough information to recommend the use of Remedisvir and other antivirals in critically ill COVID-19 patients.
Gilead, who questioned the WHO’s findings, said in an emailed statement: “We believe primary care physicians recognize the clinical benefit of Vecleri based on strong evidence from several controlled studies. randomized. ”
ESICM represents thousands of anesthesiologists, respiratory therapists, nurses and other critical care professionals in more than 120 countries.
(This story is not edited by NDTV employees and is automatically generated from a syndicated feed.)